Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

@article{Land2006PatientReportedSA,
  title={Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial},
  author={S. Land and D. Wickerham and J. Costantino and M. Ritter and V. Vogel and M. Lee and E. Pajon and J. Wade and S. Dakhil and James B. Lockhart and N. Wolmark and P. Ganz},
  journal={JAMA},
  year={2006},
  volume={295},
  pages={2742-2751}
}
ContextTamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown.ObjectiveTo compare the differences in patient-reported outcomes, quality of life [QOL], and symptoms in Study of Tamoxifen and Raloxifene (STAR) participants by treatment assignment.Design, Setting, Participants, and InterventionsSTAR was a double-blind, randomized phase 3 prevention trial designed to evaluate the relative efficacy of raloxifene vs… Expand
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
TLDR
Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer. Expand
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
TLDR
Given the similar efficacy of tamoxifen and anastrozole for women older than age 60 years, decisions about treatment should be informed by the risk for serious adverse health effects and the symptoms associated with each drug. Expand
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
  • P. Ganz, S. Land, +13 authors S. Swain
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
Premenopausal women with breast cancer receiving adjuvant chemotherapy are at risk for amenorrhea, and treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity. Expand
The use of tamoxifen and raloxifene for the prevention of breast cancer.
TLDR
The NSABP Study of Tamoxifen and Raloxifene in a population of healthy postmenopausal women at increased risk for breast cancer to determine the relative effects on the risk of invasive breast cancer. Expand
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.
TLDR
Exemestane given for prevention has limited negative impact on menopause-specific and health-related QOL in healthy postmenopausal women at risk for breast cancer. Expand
Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women
TLDR
The BCPT Eight Symptom Scale (BESS) can be clustered into clinically relevant and reproducible factors that may be useful in future outcomes research. Expand
Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.
TLDR
Attention should be given to the increased symptom burden associated with ET, and better efforts should be made to address patient-reported outcomes. Expand
Role of hormones in cancer prevention.
  • V. Vogel
  • Medicine
  • American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
  • 2014
TLDR
Of the 50 million white women in the United States aged 35 to 79, 2.4 million would have a positive benefit/risk index for chemoprevention, and both tamoxifen and raloxifene reduce the incidence of in situ cancers. Expand
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
  • V. Vogel
  • Medicine
  • Expert review of anticancer therapy
  • 2009
TLDR
The STAR trial has shown that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of adverse events but a nonstatistically significant higher risk of noninvasive breast cancer. Expand
Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial
TLDR
Bazedoxifene was associated with an overall favorable safety and tolerability profile in postmenopausal women with osteoporosis over 5 years of therapy, consistent with findings at 3 years. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
TLDR
Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer. Expand
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
TLDR
Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene, mainly in the United States and Europe. Expand
Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
TLDR
Women need to be informed of the increased frequency of vasomotor and gynecologic symptoms and problems of sexual functioning associated with tamoxifen use, according to the initial report from the health-related quality of life component of the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. Expand
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
TLDR
In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture and was associated with a lower incidence of breast cancer. Expand
Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial.
TLDR
The successful integration of HRQL data collection into this clinical trial attests to its value as a safety-monitoring end point and as an explicit and measurable outcome for the entire trial. Expand
Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials.
TLDR
The long-term use of tamoxifen and other selective estrogen response modulators as preventive agents in high-risk groups has been questioned, but there is no evidence of treatment-related side effects that affect women's psychosocial and sexual functioning. Expand
Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study.
TLDR
Physicians need not be overly concerned that treatment with tamoxifen will increase the risk for or exacerbate existing depression in women, but physicians should continue to screen for and treat or refer potential cases of depression encountered in routine clinical practice. Expand
Quality of Life and Tamoxifen in a Breast Cancer Prevention Trial
TLDR
The tamoxifen arm did show consistent increases in vasomotor and gynecological symptoms, as well as difficulties in certain domains of sexual functioning, and it is concluded that an informed discussion with a woman considering tamoxIFen therapy should include these points in the risk‐benefit discussion. Expand
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
TLDR
Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease. Expand
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
TLDR
Raloxifene at a dose of 120 mg/day, but not 60 mg/days, resulted in reduced risk of cognitive impairment in postmenopausal women. Expand
...
1
2
3
4
...